India, May 15 -- India stands at a pivotal moment in the evolution of cell therapy. Once considered a frontier accessible only in the United States and Europe, CAR-T therapy is now beginning to take root on Indian soil. With the approval of ImmunoACT's NexCAR19 - India's first homegrown CAR-T therapy - and the emergence of pioneering companies such as Immuneel Therapeutics and Intas Pharmaceuticals, the country has taken its first meaningful steps toward building a domestic CAR-T ecosystem. Translating this early momentum into a scalable, globally competitive industry will require addressing critical gaps in manufacturing infrastructure, process development capability, and regulatory readiness.

Understanding CAR-T Therapy and Its Manufac...